Cytokinetics: CEO Talks Down Buyout Prospects

Parradee Kietsirikul Shares of Cytokinetics (NASDAQ:CYTK) are down 40% from early January highs as bullish investor sentiment driven by positive SEQUOIA phase 3 results of aficamten and buyout speculation waned, initially after new rumors surfaced that Novartis walked away, and more recently, after CEO Blum talked down the buyout prospects on the earnings call in late February, and this week at the Leerink Healthcare Conference.   Seeking Alpha, TradingView The stock is down more than 20% since my late  ...